Centre Hospitalier General

At Centre Hospitalier General in Gonesse, the neurology department is heavily involved in clinical studies focused on multiple sclerosis and related immune-mediated disorders. The trials examine whether new and established treatments can better control disease activity, reduce relapses, and slow disability progression in people living with relapsing, progressive, and stable forms of the disease.

• Evaluating new and existing therapies for relapsing multiple sclerosis and treatment-naïve patients
• Studying approaches to slow progression in primary progressive multiple sclerosis and secondary progressive multiple sclerosis
• Assessing treatment strategies that may improve long-term control of neurological disease

These studies aim to improve everyday care by identifying options that may offer better symptom control, fewer relapses, and more durable protection against worsening disability.

The site also conducts research in cardiovascular and nervous system diseases, with a strong focus on acute stroke care. These trials explore treatment strategies for large vessel occlusion and large-core ischemic stroke, aiming to improve recovery and functional outcomes after a major brain blood-flow event.

• Testing treatment strategies for large ischemic stroke and large vessel occlusion
• Comparing care approaches to improve functional outcome after stroke
• Supporting better decision-making in urgent cerebrovascular care

Research in this area is designed to help determine which emergency treatments may offer the best chance of preserving independence and reducing disability after stroke.

Clinical research at the site extends into bacterial infections and critical care, including studies in septic shock and severe infections caused by resistant bacteria. These trials are intended to improve outcomes for hospitalized patients, especially those in the intensive care unit.

• Assessing supportive treatment for septic shock in critically ill adults
• Studying care options for severe infections due to ESBL-producing bacteria
• Evaluating infection management strategies that may reduce mortality and complications

This work reflects a practical focus on safer and more effective treatment choices for patients with serious infections and life-threatening critical illness.

The trial portfolio also includes broader immune system diseases and virus-related conditions, showing the department’s interest in how inflammation and immune responses affect patient outcomes. While the main concentration remains on neurology, this research contributes to a wider understanding of disease control in complex medical conditions.

• Exploring therapies that modify abnormal immune activity
• Supporting studies that may improve care in infection-related illness
• Investigating treatment effects across chronic and acute disease settings

Overall, the research environment at Centre Hospitalier General combines specialty care with clinically relevant studies aimed at improving treatment effectiveness and patient outcomes across several important disease areas.